Literature DB >> 33289919

Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations.

Camilla Hansen Nejstgaard1,2,3,4, Lisa Bero5, Asbjørn Hróbjartsson1,3,4, Anders W Jørgensen6, Karsten Juhl Jørgensen2, Mary Le7, Andreas Lundh1,3,4,8.   

Abstract

BACKGROUND: Treatment and diagnostic recommendations are often made in clinical guidelines, reports from advisory committee meetings, opinion pieces such as editorials, and narrative reviews. Quite often, the authors or members of advisory committees have industry ties or particular specialty interests which may impact on which interventions are recommended. Similarly, clinical guidelines and narrative reviews may be funded by industry sources resulting in conflicts of interest.
OBJECTIVES: To investigate to what degree financial and non-financial conflicts of interest are associated with favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews. SEARCH
METHODS: We searched PubMed, Embase, and the Cochrane Methodology Register for studies published up to February 2020. We also searched reference lists of included studies, Web of Science for studies citing the included studies, and grey literature sources. SELECTION CRITERIA: We included studies comparing the association between conflicts of interest and favourable recommendations of drugs or devices (e.g. recommending a particular drug) in clinical guidelines, advisory committee reports, opinion pieces, or narrative reviews. DATA COLLECTION AND ANALYSIS: Two review authors independently included studies, extracted data, and assessed risk of bias. When a meta-analysis was considered meaningful to synthesise our findings, we used random-effects models to estimate risk ratios (RRs) with 95% confidence intervals (CIs), with RR > 1 indicating that documents (e.g. clinical guidelines) with conflicts of interest more often had favourable recommendations. We analysed associations for financial and non-financial conflicts of interest separately, and analysed the four types of documents both separately (pre-planned analyses) and combined (post hoc analysis). MAIN
RESULTS: We included 21 studies analysing 106 clinical guidelines, 1809 advisory committee reports, 340 opinion pieces, and 497 narrative reviews. We received unpublished data from 11 studies; eight full data sets and three summary data sets. Fifteen studies had a risk of confounding, as they compared documents that may differ in other aspects than conflicts of interest (e.g. documents on different drugs used for different populations). The associations between financial conflicts of interest and favourable recommendations were: clinical guidelines, RR: 1.26, 95% CI: 0.93 to 1.69 (four studies of 86 clinical guidelines); advisory committee reports, RR: 1.20, 95% CI: 0.99 to 1.45 (four studies of 629 advisory committee reports); opinion pieces, RR: 2.62, 95% CI: 0.91 to 7.55 (four studies of 284 opinion pieces); and narrative reviews, RR: 1.20, 95% CI: 0.97 to 1.49 (four studies of 457 narrative reviews). An analysis combining all four document types supported these findings (RR: 1.26, 95% CI: 1.09 to 1.44). One study investigating specialty interests found that the association between including radiologist guideline authors and recommending routine breast cancer screening was RR: 2.10, 95% CI: 0.92 to 4.77 (12 clinical guidelines). AUTHORS'
CONCLUSIONS: We interpret our findings to indicate that financial conflicts of interest are associated with favourable recommendations of drugs and devices in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews. However, we also stress risk of confounding in the included studies and the statistical imprecision of individual analyses of each document type. It is not certain whether non-financial conflicts of interest impact on recommendations.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2020        PMID: 33289919      PMCID: PMC8092573          DOI: 10.1002/14651858.MR000040.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  137 in total

1.  Pharmacists, pharmaceutical manufacturers, and conflicts of interest.

Authors:  David Banks
Journal:  Am J Health Syst Pharm       Date:  2005-09-01       Impact factor: 2.637

2.  Conflicts of interest and clinical recommendations: comparison of two concurrent clinical practice guidelines for primary immune thrombocytopenia developed by different methods.

Authors:  James N George; Sara K Vesely; Steven H Woolf
Journal:  Am J Med Qual       Date:  2013-04-02       Impact factor: 1.852

3.  Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study.

Authors:  Elie A Akl; Pierre El-Hachem; Hiba Abou-Haidar; Ignacio Neumann; Holger J Schünemann; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2014-06-23       Impact factor: 6.437

4.  What is in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines.

Authors:  Lisa Bero
Journal:  J Clin Epidemiol       Date:  2014-08-15       Impact factor: 6.437

5.  Does the pharmaceutical industry influence guidelines?: two examples from Germany.

Authors:  Gisela Schott; Claudia Dünnweber; Bernd Mühlbauer; Wilhelm Niebling; Henry Pachl; Wolf-Dieter Ludwig
Journal:  Dtsch Arztebl Int       Date:  2013-09-02       Impact factor: 5.594

Review 6.  An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.

Authors:  Andrew C Bennett; Charles L Bennett; Bartlett J Witherspoon; Kevin B Knopf
Journal:  Expert Opin Drug Saf       Date:  2019-09-18       Impact factor: 4.250

7.  Drug firms, the codification of diagnostic categories, and bias in clinical guidelines.

Authors:  Lisa Cosgrove; Emily E Wheeler
Journal:  J Law Med Ethics       Date:  2013       Impact factor: 1.718

Review 8.  Association of Industry Sponsorship With Outcomes of Nutrition Studies: A Systematic Review and Meta-analysis.

Authors:  Nicholas Chartres; Alice Fabbri; Lisa A Bero
Journal:  JAMA Intern Med       Date:  2016-12-01       Impact factor: 21.873

9.  Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study.

Authors:  Peter Lurie; Harinder S Chahal; Daniel W Sigelman; Sylvie Stacy; Joshua Sclar; Barbara Ddamulira
Journal:  BMJ       Date:  2015-06-10

10.  Food for thought? Potential conflicts of interest in academic experts advising government and charities on dietary policies.

Authors:  Alex Newton; Ffion Lloyd-Williams; Helen Bromley; Simon Capewell
Journal:  BMC Public Health       Date:  2016-08-05       Impact factor: 3.295

View more
  3 in total

1.  Addressing Conflicts of Interest and Conflicts of Commitment in Public Advocacy and Policy Making on CRISPR/Cas-Based Human Genome Editing.

Authors:  Alexander Christian
Journal:  Front Res Metr Anal       Date:  2022-04-27

2.  Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations.

Authors:  Camilla Hansen Nejstgaard; Lisa Bero; Asbjørn Hróbjartsson; Anders W Jørgensen; Karsten Juhl Jørgensen; Mary Le; Andreas Lundh
Journal:  Cochrane Database Syst Rev       Date:  2020-12-08

3.  Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review.

Authors:  Camilla H Nejstgaard; Lisa Bero; Asbjørn Hróbjartsson; Anders W Jørgensen; Karsten J Jørgensen; Mary Le; Andreas Lundh
Journal:  BMJ       Date:  2020-12-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.